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Cost Per Cure of telaPrevIr aNd BoCePrevIr IN treatmeNt-Naïve 
GeNotyPe 1 HePatItIs C PatIeNts wItH f2 fIBrosIs IN BrazIl
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Janssen Cilag Farmaceutica, São Paulo, Brazil
Objectives: Compare the cost per cure of telaprevir of peginterferon and ribavirin 
(TVR+PR) compared to boceprevir plus peginterferon and ribavirin (BOC+PR) in 
the treatment of METAVIR scale F2 patients with previously untreated chronic 
hepatitis C genotype 1 in the Brazilian public (SUS) and private (SS) health care 
system. MethOds: Treatment costs considered drug acquisition costs of TVR+PR 
and BOC+PR from a public and private payer perspective in Brazil. The cost/cure 
was defined as the cost/sustained virological response (SVR) according to the 
phase 3 trials of TVR and BOC. The SVR rate for TVR+PR was defined as 79% and 
49% for PR in patients with F2 fibrosis. Based on the SPRINT-2 trial, the SVR-rate 
for F2 patients treated with BOC+PR was assumed 57%, average between F0/F1 
and F3/F4 patients, compared to 38% for PR. Treatment duration, based on the 
extended rapid virological response (eRVR), was taken from the respective trials 
of BOC (eRVR = 44%) and TVR (eRVR = 58%). Deterministic sensitivity analysis 
was carried out for the eRVR rate. Results: In the SUS, TVR+PR had an average 
treatment cost of R$ 40.093 per F2 fibrosis patient compared to R$ 36.185 with 
BOC+PR. Considering the SVR rate and the sensitivity analysis, TVR+PR had a 
cost/SVR of R$ 50.751 (R$ 49.797-R$ 51.705) compared to R$ 63.481 (R$ 61.771-R$ 
65.191) with BOC+PR. In the private health care system, TVR+PR had a treatment 
cost of R$ R$ 88.508 per F2 fibrosis patient compared to R$ 82.518 with BOC+PR. 
Considering the cost/SVR and sensitivity analysis, TVR+PR had a cost/SVR of R$ 
112.036 (R$ 108.253-R$ 115.819) compared to BOC+PR with a cost/SVR of R$ 144.768 
(R$ 140.631-R$ 148.905) per F2 patient in the SS. cOnclusiOns: Compared to 
BOC+PR, TVR+PR was a more cost-effective treatment of F2 fibrosis patients in 
both public and private health care systems.
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Objectives: To evaluate the cost-effectiveness of peginterferon (PEG INF) alfa and riba-
virin for the treatment of children and young people ages 3 to 17 years with Chronic 
Hepatitis C (CHC), from the perspective of the NHS in England and Wales. This analysis 
was submitted to NICE as part of a submission dossier for the multiple technology 
appraisal of PEG INF alfa and ribavirin for the respective population. MethOds: A 
Markov model was developed based on previous economic evaluations for treatment 
of adults with CHC with PEG INF alfa and ribavirin. The model evaluated the cost-effec-
tiveness of PEG INF alfa-2a or alfa-2b and ribavirin, and supportive care, for the treatment 
of people aged 5 to 17 years. An additional analysis was conducted on 3 and 4 year olds 
comparing supportive care to PEG INF alfa-2b and ribavirin in line with license. The 
cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER) 
from the perspective of the NHS over a lifetime horizon. The results were assessed 
overall and by age and genotype subgroups. Results: The results reported that both 
combinations of PEG INF alfa and ribavirin dominated supportive care for all patients. 
Driven by small variation in the comparative efficacy and costs, the comparison between 
PEG INF alfa-2a and alfa-2b, in combination with ribavirin, showed that PEG INF alfa-2b 
dominated PEG INF alfa-2a overall and in the following subgroups: 5 to 8 years, 14 to17 
years and genotypes 2/3. The ICER for the 9 to13 years subgroup was £4,697. PEG INF 
alfa-2a dominated PEG INF alfa-2b for the other genotype subgroup cOnclusiOns: The 
results of the economic evaluation demonstrated that treatment with either combina-
tion of PEG INF alfa and ribavirin is a cost-effective treatment option for children and 
young people aged 3 to 17 years with CHC.
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Objectives: Streptococcus pneumoniae is presumed to be the major etiology 
agent responsible for a significant amount of meningitis, bacteremia and sepsis 
(invasive pneumococcal disease; IPD) as well as Community Acquired Pneumonia 
(CAP) and Acute Otitis Media (AOM). The Czech Republic (CR), as well as many 
other European countries have only a limited local evidence on the underlying 
epidemiology. The objective was to estimate the expected outcomes, costs, cost-
effectiveness of the pediatric national immunization program (NIP) with 13-valent 
pneumococcal conjugated vaccine (PCV13) and 10-valent pneumococcal conju-
gated vaccine (PCV10) as a comparator among specific populations of children 
and adults in preventing and reducing the incidence of IPD, CAP and AOM in 
CR. MethOds: A Markov decision-analytic model was developed to examine 
impacts of infant vaccination with PCV13 versus PCV10. PCV13 direct effectiveness 
was extrapolated from PCV7 efficacy data from clinical trials, using assumptions 
regarding serotype prevalence and PCV13 protection against additional serotypes, 
while indirect (herd) effect was extrapolated from US surveillance data following 
universal PCV7 use. The local epidemiology and cost data were used to achieve 
maximum national specificity. Results: Model predicts incremental EUR 64.5 
million for the PCV13 NIP from the payer’s perspective in the 10-year horizon, as 
compared to PCV10. This would lead to an reduction in IPD, all cause inpatient and 
outpatient CAP and AOM by approximately 921, 22 900, 56 796 and 40 598 cases, 
respectively, thus savings EUR 35.4 million. This gives a total cost of EUR 29.0 mil-
lion in the 10 years. The incremental cost per LYG or QALY gained is estimated 
as EUR 929 or EUR 1 164, respectively, from the payer’s perspective as compared 
to PCV10. cOnclusiOns: Comparing the national GDP per capita with the WHO 
Objectives: To estimate the cost-effectiveness (CE) of the 3 echinocandins 
(Anidulafungin, Caspofungin and Micafungin) and generic Fluconazole in the treatment 
of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish Intensive 
Care Unit (ICU) setting. MethOds: A 4 arm decision tree model was developed with the 
3 echinocandins and generic Fluconazole as first line treatment. In case of treatment 
failure, a 2nd line treatment was administered (Liposomal Amphotericin-B following 
the echinocandins and either one of the 3 echinocandins for Fluconazole arm). After 2nd 
line failure, treatment was discontinued. Total treatment length was 14 days. Efficacy 
and safety (adverse events/lack of efficacy) parameters where obtained from a mixed-
treatment-comparison and a meta-analysis respectively. Efficacy was considered as 
first line success (Anidulafungin 75.32%; Micafungin 71.65%; Caspofungin 70.62%; and 
Fluconazole 56.7%). Length of the first and the second line were elicited using experts’ 
opinion through Delphi methodology. Daily drug acquisition costs were considered 
only. The CE was expressed as an incremental cost-effectiveness ratio (ICER). Univariate 
sensitivity analyses were also applied and included, length of treatment in 1st or 2nd line 
and finally drug dosages calculated as per SmPC recommendations according to dif-
ferent patient characteristics. Results: Total costs of IC treatment for Anidulafungin, 
Micafungin, Caspofungin and Fluconazole were € 5,552; € 5,985; € 6,350; € 1,654 respec-
tively. Anidulafungin was dominant compared to Micafungin and Caspofungin. 
Anidulafungin and Micafungin were cost-effective (€ 20,934; 29.576€ respectively) 
compared to Fluconazole (CE threshold of € 30,000). Sensitivity analyses revealed that 
ICER was sensitive to increases in the length of the 1st and 2nd line treatments, although 
Anidulafungin was cost-effective in all scenarios. cOnclusiOns: Based on the model’s 
assumptions, Anidulafungin is cost-saving compared to Micafungin and Caspofungin 
and cost-effective vs. Fluconazole in the treatment of patients with confirmed invasive 
candidiasis from a Spanish Hospital ICU perspective.
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Objectives: The ventilator associated pneumonia (VAP) refers to the pneumonia 
that appears after 48-72 hours of endotracheal intubation and is the most common 
nosocomial infections in patients receiving mechanical ventilation. Late-onset VAP 
is responsible for prolonged ICU stay and higher mortality rates (24 to 50% and can 
even increase to 76%), which explains the importance of using more effective anti-
biotics depending on the severity of each case. The aim of this study is to assess 
the cost-effectiveness (CE) of linezolid against vancomycin in the treatment of VAP, 
from the public health care perspective. MethOds: A cohort of patients with VAP 
was simulated using a decision-tree model to compare costs and effectiveness of 
linezolid (600 mg/12 hours) and vancomycin (1 g/12 hours). Effectiveness measures 
were: microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered (inpatient 
costs, medication expenses, adverse events costs). Effectiveness and epidemiologic 
data were retrieved from published literature. Local costs (2013 US$) were gathered 
from the official databases of Jamaican Health System. Monte Carlo probabilistic 
sensitivity analysis (PSA) was constructed. Results: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate was 
higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected ICU LOS 
was 14 days for linezolid and 17 days for vancomycin, ward LOS was 14 and 24 days 
with linezolid and vancomycin, respectively. Mortality rate was found lower in the 
linezolid arm (10.13%) in comparison to vancomycin (15.74%). Overall costs per patient 
were $36721.65 with linezolid and $40776.82 with vancomycin. In the CE incremental 
analysis, linezolid appeared as the cost-saving option. PSA outcomes support the 
robustness of these findings. cOnclusiOns: Linezolid resulted as the cost-saving 
therapy for treating VAP adult patients in Jamaica.
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Objectives: Boceprevir plus P/R has demonstrated a superior clinical profile, com-
pared to P/R alone, in the treatment of genotype 1 chronic hepatitis C (G1-CHC) 
patients. The objective of this study was to evaluate the cost-effectiveness of 
BOC/P/R therapy for treatment naïve and treatment experienced G1-CHC patients 
in Greece. MethOds: A Markov-model simulating the quality-adjusted life years 
and corresponding costs of G1-CHC treatment provided the basis of the analyses. 
The BOC/P/R regimens recommended in the label for treatment naïve and treat-
ment experienced patients were compared to P/R to calculate incremental costs and 
outcomes. The inputs for the model were derived from post-hoc subset analyses of 
SPRINT-2 and RESPOND-2 data. Resource use for patient monitoring and treatment 
of events was elicited via expert panel. Lifetime horizon with 3% discount rate was 
used and the perspective of analysis was third-party payers. Results: BOC-based 
therapy was projected to reduce liver complications (decompensated cirrhosis, hepa-
tocellular carcinoma, liver transplant and liver–related death) by 44% and 49-53% 
in treatment naïve and experienced patients, respectively, leading to correspond-
ing gains of 0.87 and 1.25 QALYs per patient. Taking into account medication costs, 
treatment and management of events, the ICER for BOC-based therapy versus P/R 
were estimated at 10,003€ /QALY and 10,852€ /QALY for treatment naïve and expe-
rienced patients, respectively. Extensive sensitivity analyses indicated that results 
were robust. cOnclusiOns: Based on the results of this analysis, the addition of 
Boceprevir to P/R for treatment of G1 CHC patients can be a cost-effective treatment 
option in the Greek health care setting.
